Current Strategies And Business Model Marketing Essay

rate of flow Strategies And Business Model Marketing EssayThis study is considered about the AstraZeneca Plc connection by applying much strategies to their business branch. In this review it considered the fundamental opportunities and challenges of AstraZeneca Plc participation for business process by exploitation to a giganticer extent(prenominal) strategies. This study is unavoid fit to increase their search and look conscious of medicines.It abstract the internal arranging to produce more(prenominal) property and apostrophize conscious of the merchandise and a alike(p) it analysis the fortissimo and weakness of the keep ships connection. It leads to more growth, gross gross gross sales and revenue of pharmaceutic industry.Table of ContentsS.No.ParticularsPage No.1. base32. close to AstraZeneca33.Task I44.Task II115.Analysis of AstraZeneca166.Recommendations167.Conclusion178.References17IntroductionThe pharmaceutical industries atomic number 1 8 leads to more growth in the sweet harvest-festival exploitation. Nowadays at that place atomic number 18 more untested medicines and drugs atomic number 18 created by the biological researchers. there is more business system and marting strategies atomic number 18 used to break out their market and demand in the pharmaceutical industry. here AstraZeneca Company has recommended to applying the more schema to this study. In this study we argon apply descriptive research to this review. For this study, the reference has taken from non-homogeneous sources like journal, article, remuneration links, magazines, textbooks etc.About AstrazenecaAstraZeneca is one of the leading pharmaceutical company in the orb. The company has formed in the year 1999, after the merger of Swedens Astra AB and UKs Zeneca Group plc. David Brennan is the CEO of the company. The head quarters of the company are in London, UK. The AstraZeneca has have sex across number of invigorated crop into the market. AstraZeneca is one of the terce largest pharmaceutical company in the orbit. There is largest interrogation information core group has formed and it invested about 16 million for every day. The research and tuition has produced lot of untestedborn yield for tail assemblycer, cardiovascular, gastrointestinal etc.. after the company has unify and it produces a lot of rude(a) outputs and medicines for the patients and doctors. It has aimed to produce a great step medicine and to innovate more medicines for lot of diseases. And it feel objective to remedy corporate responsibility to the society and voiceholder.http//www.astrazeneca.co.uk/about-us/ (date 11-01-2010, era 3.15p.m)There are 66000 employees are working in the AstraZeneca among Europe, Asia, US, Africa etc. The AstraZeneca has 29 manufacturing Sites among the 19 countries. In 2006 the company has achieved $26.5 zillion of over all profit. In 2008 the company has achieved and improved $31. 5 billion profit.http//www.astrazeneca.co.uk/about-us/keyfacts?itemId=4142279nav=yes (date 11-01-2010, quantify 3.35p.m)TASK IChallenges faced by the AstraZenecaThe AstraZeneca is a largest pharmaceutical company in the world. It works well-nigh 100 countries in the world. There are more competition for pharmaceutical industry. The contentions are Johnson Johnson, merek co, Novarties, Pfizer etc.. the competitor are in world level. So the company has compete world wide, and it challenges to rude(a)(prenominal) competitor in new ingathering and increase and research. There is more challenges the company has faced by the other outer environment. So the AstraZeneca has develop new medicines for cancer and other diseases. It mustinessiness aim to bounce spite relief to the society.http//www.computing.co.uk/computing/news/2255053/case-study-astrazeneca (date 11-01-2010, time 4.12p.m)The AstraZeneca has innovate new harvests and it brook drug parentage for cancer, card iovascular and other diseases. So it aims to reduce the salute and it improve drug pipeline for challenging the competitor circle.AstraZeneca has improved its challenges by the way of reducing the cost of medicines and improving the drug pipeline for various diseases. They increase their research and Development centre to the world and it increase carrefour purpose in medical field. Their vision to increase their market to world wide and innovation of great medicines and it must increase the stakeholder prize. Mostly AstraZeneca research nurture is in Sweden, U.K and U.S. because there is more drugs and raw material has useable in the cross place. And similarly they has more talented person in a biological fields. strategical look for and Development Issues for challenging competitorThe RD manager is only if the responsible for the suggesting and implementing the new medicines for the diseases and it must increase the drugs pipeline for the patients. They are improving the ir new harvest-feast discipline by conflux the RD segment and technologies.The RD managers Job includesChoosing among alternative new applied science to use indoors the AstraZeneca pharmaceutical company,Development new methods of embodying the new engine room in new products and processes andIt deploying resources so that the new engineering and medicines can be successfully implemented.Research Development IntensityThe company must make available the resources undeniable for potent research and phylogenesis. The AstraZeneca has spend around $3.9 billion for its research and schooling. The AstraZenecas R D Intensity is a principal means of gaining market share in global competition. So the R D department has centre the drug pipelines for distinct diseases and it crumple pain relief to the patients. The research and victimization has providing more innovative medicine for the patients to give more effective breastplate for the diseases.Technology CompetenceThe te chnology competence is used for both development and technology development in the R D department. The AstraZeneca has more technology to improve its each drugs pipeline to lead the pharmaceutical market. The R D department has improve their technology development for the growth full product of Arimidex, Crestor, Nexium, Seroquel, Symbicort etc., the product which develop in R D department for cancer, cardiovascular, gastreointestinal diseases, bronchial asthma and chronic obstructive pulmonary diseases etc., So it deem the more technology competence for leading the market.http//www.astrazeneca.co.uk/about-us/keyfacts?itemId=4142279nav=yes (date 11-01-2010, time 6.19p.m)Technology TransferThe Astra and Zeneca pharmaceutical company has merging together for improving its R D department and innovation of medicines for disease. So it transfers the technologies to improve the research and development process of each company. The technology transfer has given more challenges toward s competitor of other pharmaceutical industry.Research and Development MixThe R D mix has includes everything that would help to sales, select control, distinguishable medicines and technology development of the AstraZeneca pharmaceutical industry. The company has increase its growth of new product and at the equal time it support whole tone control of the medicines. The AstraZeneca R D development has got license to innovation of new medicines for the patients and it has intellectual property rights towards its new products. The R D department has maintain more expensive quality control from biological lab with using effective technologies, sales growth, technical laboratories, development of biological labs and more research information of medicines etc.. strategical Marketing ChallengesThe AstraZeneca Companys marketing manager should be center on the client wants and product cost. Here the marketing manager must acquaint the market position and segmentation, marketing mix and the product life bicycle for facing leading competition among the world.Market position and SegmentationThis pharmaceutical industry has cogitate the hospital and patients who are really affected by the diseases, for new research development and it must increase the focused sales among competitors. The AstraZeneca has increased its sales in selected areas. The market has segmented by the new product and new medicines for the patients.Marketing MixThe marketing mix is like 4 Ps. Promotion, Price, Place, Product are the marketing mix. The AstraZeneca product has more competition, and it energise marketing mix to improve the quality and reducing the cost of medicines, which have the suitable place to sell the medicines to the customer.Product life cycleAstraZeneca has a product life cycle. In 1999 the Astra and Zeneca pharmaceutic company has merging and it has a introduction layer of the medicine. In 2000 it has an effective growth towards its medicines especially the pro duct of Arimidex, Crestor, Nexium, Seroquel, Symbicort are have efficient growth. After some catamenia it reached the due date period and in summer time it has a declining stage of the product. This pharmaceutical company has product life cycle, it depends upon the environment and competitor. If it have various new product development means it have more maturity period of this laboratory industry.Source Philip kotler Gary Armstrong, Principle of Marketing, Prentice Hall of India, 2007. (date 10-01-2010, time 7.13p.m) get a line Opportunities of AstraZenecaThe Astra Zeneca has innovate more product and merging with other leading pharmaceutical company for develop more new product and medicines for leading proximo market among competitor. The AstraZeneca has developing its more valuable new product development and improve drugs pipelines. There is using more technologies and using developing more biological labs for developing its new medicines for the product.http//www.independe nt.co.uk/news/business/the-player-tom-mckillop-chief-executive-of-astrazeneca-creating-the-right-chemistry-1130990.html (date 11-01-2010, time 5.33p.m)Opportunities in Research and DevelopmentThere is more opportunities for providing new product and medicines to the customer from merging the pharmaceutical company and other biological labs. There are 22000 employees and they were expert in biological medicines are working research and development field. So they able to dedicate more new products and medicines to the rare diseases and it able increase its sales growth.AstraZeneca has improved its new pharmaceutical product of its round-the-clock process. It must build more biological and innovation activities towards its new medicines.The AstraZeneca laboratories have more building capabilities towards its biological labs and build to research in new medicines from agri-chemical industries.This pharmaceutical industry has very talented in biological laboratories and farming(a) chem ical business for new medicines. So it have more valuable resources and talented employees in biological industries for the process of rising development.This deliver that it develops more opportunities for its sustained growth in new product development and sales growth.Sustainable development of AstraZenecaAstraZeneca has focus to patronage the continuous new product development. AstraZeneca has improved its research and development centre to the world wide for it sustain to increase its new medicines and innovation activities in pharmacy industry.Economic The pharmaceutical industrial has shock absorber on economic for increasing its economic harbor from its new products. So AstraZeneca Plc Company has more depended upon the economic and also in 2004 it increases its economic growth to the country. It has more prospect to improve its economic development of the new product.Social AstraZeneca has more valuate in tender responsibilities and to give effective and protected m edicine to the patients. So it has a impact in social and other things among the pharmaceutical company.Environment The Company has environment impact towards its new medicines and research in biological industry. The environment should have the sense about the diseases and new medicines of its protection. So the AstraZeneca has impact and opportunity in environment level of its new product development.Krishnamoorthy, Environmental Management, published by PHI, 2006. (date 10-01-2010, time8.23p.m)TASK IIInternal and Organizational Analysis of AstraZeneca Pharmaceutical IndustriesIt must look at the environment, which AstraZeneca has to face in the market and the opportunities and threats that arise from it. It has an analysis towards its internal and organizational factors to improving its efficiency among competitor in world wide. The organization is depending upon the strength weakness of organization and it turned as opportunity for upcoming.HistoricalThe AstraZeneca company h as more sales after the period of 1999. Because the ii pharmaceutical company has merging together and it gave a lot of new products and researches to the society. It 2006 the sales growth is $26.5 billion and in 2008 the sales growth has come around $31.5 billion. The companies profit also increases and it beyond its growth level. After 2008 only it became a down in share market and share value of the product. In that summer time the demand has decreased and the profit has or so down.NormativeThis criterion make use of the judgment, what ought to be the level of exertion to classify and element as a strength or a weakness?. Based on industrial practices and personal opinion, norms for evaluation can be developed. The research and development has continuous growth of new product and in 2008 the revenue is $31.5 billion. So if the process of new product stage is declining in the research, then it will be says as weakness. The AstraZeneca company has continuous process of new produ ct. It has a sustainable environment to market their product to the customer. AstraZeneca has come across number of new products and medicines for the cancer, cardiovascular, intestine etc..Competitive coincidenceThis criterion was the action of successful competitors or potential competitors. The new medicines are produced by the usage of drugs and some other agri-products. The drugs must used in a certain level. It should not go beyond of the level of drugs in to medicines. The new product will be in quality conscious. vital factor for SuccessEach business is unique and has a stage of minimum objectives (i.e) to improve their drugs pipeline and they can set minimum factors of medicine, which should give more effective to the patients. So they are the strength of the company.The critical factors are considered in the pharmaceutical industry and it has able to give continuous growth to the society. This will consider to over all strength to the resources of this pharmacy industry. Pearce, Strategic Management, PHI, 2006 (date 12-01-2010, time 3.15p.m)Strength and Weakness of the AstraZeneca Plc.Internal FactorsStrengthWeaknessto a greater extent research centres are in various countries.Brand NameHaving skill, incur and quality of their researchers and lab staffs.Agricultural chemical industries are working towards it. businesslike development of R D investment.Key product Development physical exertion of various technologies into the biological labs.Competitors are in world wide.The shareholder value is less when compare to other competitor.They invest $16 million to R D for every day to day work. They are dumping their investment to their research itself.Major competitor are Johnson Johnson, Pfize, Bayer, Abbot Laboratories etc..In AstraZeneca Pharmaceutical industry has more strength of this company is, investment of research and development and continuous growth of new product development. The major weakness of AstraZeneca is a competitor. It has work s over 100 countries around the world. so they are marketing their products in the International market. this pharmaceutical industry has compete their compete their competitor by the way of merging their industry.AstraZeneca is a largest pharmaceutical company in the world. The market has more competitors in pharmacy industry. The major competitor are Johnson Johnson, Bayer, Pfize, Novarties, Abbot Laboratories etc.. AstraZeneca has sustained their product by producing new product and medicines by the activity of research and development.http//www.ingentaconnect.com/content/fm/pme/2006/00000003/00000002/art00009 (date 12-01-2010, time 3.45p.m)Research and Development is a strong basement to this AstraZeneca pharmaceutical industry. They are investing around $ 5 billion in 2008, for the research and development activities. They are actively participated in improving drugs pipeline and they aim to achieve major great medicines in 2010. They are launches two new molecular Entity to t he develop their new medicines.Attribute measures of its strength and weaknessThese refer to statements developed to identify or list a characteristic or quality, an organization possesses or potential to possess in the near future.Our key strength is the having sustainable growth in new products development in the R D department.Our key weakness is investing more notes to research and Development.Here the strength is the research and development has a innovation of new product and development in a biological industry. But at the same time the weakness is to investing more bullion to the R D. AstraZeneca has dumping their money to R D centre sort of than other department.So it should remnant the investment to other business and other factor. But at the same time, it should concentrate is R D to improve new drug pipeline.Implementing Porters emulous strategiesIt should compete on the basis of low cost, or should us different our medicines on some basis other than cost, such as quality or service.It should we compete head to head with our major competitors for the biggest but intimately sought after share of the market.The porters competitive strategies are based on the Lower cost schema and Differentiation strategy.Lower cost strategy is followed by this pharmaceutical company, it has an ability to design, produce, and market a comparable product more efficiently than its competitors.Differentiation Strategy is focused the company, it ability to reserve unique and superior value to the buyer in terms of product quality, special features, or after-sales service.The competitive strategies are followed by different types by the way of competitive advantage and competitive scope of the pharmaceutical company.The cost leadership is considered that the pharmaceutical company has aims to broad mass market and requires in-your-face construction of efficient-scale facilities, vigorous pursuit of cost reductions from experience, tight cost and crash contro l, avoidance of marginal customer accounts, and cost minimizing areas like R D, service, sales, force, advert and so on. These companies have done in a marketing department and achieve its goal among competitors.Differentiation is aim to broad mass market and involves the creation of a product or service that is perceived end-to-end its industry as unique. This company has differentiated their product, medicines, its quality, technology, agri-products, and features of the medicines among other competitors.Cost focus is considered to focus the primary buyer group or geographic market and attempts to serve only this niche, to the exclusion of others. This company has focus the cancer, cardiovascular, gastrointestinal, infection neuroscience and respiratory and inflammation patients. They founded by hospital and they improve their quality services at the same time low cost to the patients,Differentiation Focus strategy is concentrates its particular buyer group, product line segment , or geographic market. AstraZeneca has manufacturing its different countries and it focus some diseases group, which cant get the medicine easily for particular disease. So it focus differentiated among the competitor.These are competitive strategies has adopting and implementing to the AstraZeneca Pharmaceutical industry.Neil Ritson, Strategic Management, PHI, 2006 (date 12-01-2010, time 4.35p.m)Analysis of AstraZeneca PlcAstraZeneca has mostly focuses on their new medicines and their development. They are developing their new drugs pipeline for various diseases like cancer, cardiology etc.,There are 19 research and Development centers are available at various countries also focuses in Social responsible activities and they are increases their stake holder value.The future investment of research and development and new product development must balance each other.From these analyses, this pharmaceutical company has more strength rather than the weakness. So the company has performe d well in the past records.More strategy has adopted in the review. It should used in a marketing department and it should develp these strategies for marketing department.http//www.healthlinks-events-bpc2009.co.uk/presentations/brent_vose%20tues%208th%2011.25%20Astra%20Zeneca%20Plenary%20-challenges%20and%20oportunities.pdf (date 12-01-2010, time 5.25p.m)RecommendationsAstraZeneca the pharmaceutical industry has investing more money to research and development, it means to they are dumping their only to research itself. It must also consider the marketing department to improve their effective sales growth. The R D department must come across more drug pipeline diseases like swine flue, cancer, cardiovascular, gastro intestinal, infection, neuroscience and respiratory and inflammation. The R D must use more agri product rather than the chemicals. So it leads to more quality to the patients.The company must also focus to the marketing department because there is more competitors to this industry. The company must use marketing strategy effectively which are considered into this review.ConclusionIn this review we are concluded that the company has more strength rather than the weakness because of the research and development. In future market there is more medicines are all increased by the competitor. So it should consider improving the research and development by effective biological sciences, technologies and quality conscious of fit workers. The AstraZeneca has performing in social responsibilities to the society. In future it may increase the sustainable growth in new product development.